MedTrace Logo

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 267

Last updated 2022-09-26

Study results available
· View outcomes & findings →

Summary

This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.

Conditions

  • Current or Recent History of Atrial Fibrillation

Interventions

DRUG

bucindolol hydrochloride

DRUG

metoprolol succinate

OTHER

Placebo oral capsule

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • ARCA Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Jonathan Piccini, MD · Duke University

  • Michael Bristow, MD,PhD · ARCA Biopharma, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-12-28
Completion
2017-12-28

Countries

  • United States
  • Canada
  • Hungary
  • Netherlands
  • Poland
  • Serbia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01970501 on ClinicalTrials.gov